Search Results - "Christie, Amanda"

The Requirement for Cyclin D Function in Tumor Maintenance by Choi, Yoon Jong, Li, Xiaoyu, Hydbring, Per, Sanda, Takaomi, Stefano, Joanna, Christie, Amanda L., Signoretti, Sabina, Look, A. Thomas, Kung, Andrew L., von Boehmer, Harald, Sicinski, Piotr

“…D-cyclins represent components of cell cycle machinery. To test the efficacy of targeting D-cyclins in cancer treatment, we engineered mouse strains that allow…”
Get full text

Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma by Tai, Yu-Tzu, Mayes, Patrick A., Acharya, Chirag, Zhong, Mike Y., Cea, Michele, Cagnetta, Antonia, Craigen, Jenny, Yates, John, Gliddon, Louise, Fieles, William, Hoang, Bao, Tunstead, James, Christie, Amanda L., Kung, Andrew L., Richardson, Paul, Munshi, Nikhil C., Anderson, Kenneth C.

“…B-cell maturation antigen (BCMA), highly expressed on malignant plasma cells in human multiple myeloma (MM), has not been effectively targeted with therapeutic…”
Get full text

Mediator kinase inhibition further activates super-enhancer-associated genes in AML by Pelish, Henry E., Liau, Brian B., Nitulescu, Ioana I., Tangpeerachaikul, Anupong, Poss, Zachary C., Da Silva, Diogo H., Caruso, Brittany T., Arefolov, Alexander, Fadeyi, Olugbeminiyi, Christie, Amanda L., Du, Karrie, Banka, Deepti, Schneider, Elisabeth V., Jestel, Anja, Zou, Ge, Si, Chong, Ebmeier, Christopher C., Bronson, Roderick T., Krivtsov, Andrei V., Myers, Andrew G., Kohl, Nancy E., Kung, Andrew L., Armstrong, Scott A., Lemieux, Madeleine E., Taatjes, Dylan J., Shair, Matthew D.

“…A small-molecule inhibitor of the Mediator-associated kinases CDK8 and CDK19 inhibits growth of acute myeloid leukaemia (AML) cells and induces upregulation of…”
Get full text

Selective inhibition of BET bromodomains by Knapp, Stefan, Bradner, James E, Filippakopoulos, Panagis, Qi, Jun, Picaud, Sarah, Shen, Yao, Smith, William B, Fedorov, Oleg, Morse, Elizabeth M, Keates, Tracey, Hickman, Tyler T, Felletar, Ildiko, Philpott, Martin, Munro, Shonagh, McKeown, Michael R, Wang, Yuchuan, Christie, Amanda L, West, Nathan, Cameron, Michael J, Schwartz, Brian, Heightman, Tom D, La Thangue, Nicholas, French, Christopher A, Wiest, Olaf, Kung, Andrew L

“…Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called…”
Get full text

Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models by Ng, Samuel Y., Yoshida, Noriaki, Christie, Amanda L., Ghandi, Mahmoud, Dharia, Neekesh V., Dempster, Joshua, Murakami, Mark, Shigemori, Kay, Morrow, Sara N., Van Scoyk, Alexandria, Cordero, Nicolas A., Stevenson, Kristen E., Puligandla, Maneka, Haas, Brian, Lo, Christopher, Meyers, Robin, Gao, Galen, Cherniack, Andrew, Louissaint, Abner, Nardi, Valentina, Thorner, Aaron R., Long, Henry, Qiu, Xintao, Morgan, Elizabeth A., Dorfman, David M., Fiore, Danilo, Jang, Julie, Epstein, Alan L., Dogan, Ahmet, Zhang, Yanming, Horwitz, Steven M., Jacobsen, Eric D., Santiago, Solimar, Ren, Jian-Guo, Guerlavais, Vincent, Annis, D. Allen, Aivado, Manuel, Saleh, Mansoor N., Mehta, Amitkumar, Tsherniak, Aviad, Root, David, Vazquez, Francisca, Hahn, William C., Inghirami, Giorgio, Aster, Jon C., Weinstock, David M., Koch, Raphael

“…T- and NK-cell lymphomas (TCL) are a heterogenous group of lymphoid malignancies with poor prognosis. In contrast to B-cell and myeloid malignancies, there are…”
Get full text

SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction by Inuzuka, Hiroyuki, Shaik, Shavali, Onoyama, Ichiro, Gao, Daming, Tseng, Alan, Maser, Richard S, Zhai, Bo, Wan, Lixin, Gutierrez, Alejandro, Lau, Alan W, Xiao, Yonghong, Christie, Amanda L, Aster, Jon, Settleman, Jeffrey, Gygi, Steven P, Kung, Andrew L, Look, Thomas, Nakayama, Keiichi I, DePinho, Ronald A, Wei, Wenyi

“…The effective use of targeted therapy is highly dependent on the identification of responder patient populations. Loss of FBW7, which encodes a…”
Get full text

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models by Meehan, Terrence F, Conte, Nathalie, Goldstein, Theodore, Inghirami, Giorgio, Murakami, Mark A, Brabetz, Sebastian, Gu, Zhiping, Wiser, Jeffrey A, Dunn, Patrick, Begley, Dale A, Krupke, Debra M, Bertotti, Andrea, Bruna, Alejandra, Brush, Matthew H, Byrne, Annette T, Caldas, Carlos, Christie, Amanda L, Clark, Dominic A, Dowst, Heidi, Dry, Jonathan R, Doroshow, James H, Duchamp, Olivier, Evrard, Yvonne A, Ferretti, Stephane, Frese, Kristopher K, Goodwin, Neal C, Greenawalt, Danielle, Haendel, Melissa A, Hermans, Els, Houghton, Peter J, Jonkers, Jos, Kemper, Kristel, Khor, Tin O, Lewis, Michael T, Lloyd, K C Kent, Mason, Jeremy, Medico, Enzo, Neuhauser, Steven B, Olson, James M, Peeper, Daniel S, Rueda, Oscar M, Seong, Je Kyung, Trusolino, Livio, Vinolo, Emilie, Wechsler-Reya, Robert J, Weinstock, David M, Welm, Alana, Weroha, S John, Amant, Frédéric, Pfister, Stefan M, Kool, Marcel, Parkinson, Helen, Butte, Atul J, Bult, Carol J

“…Patient-derived tumor xenograft (PDX) mouse models have emerged as an important oncology research platform to study tumor evolution, mechanisms of drug…”
Get full text

DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance by Togami, Katsuhiro, Pastika, Timothy, Stephansky, Jason, Ghandi, Mahmoud, Christie, Amanda L, Jones, Kristen L, Johnson, Carl A, Lindsay, Ross W, Brooks, Christopher L, Letai, Anthony, Craig, Jeffrey W, Pozdnyakova, Olga, Weinstock, David M, Montero, Joan, Aster, Jon C, Johannessen, Cory M, Lane, Andrew A

“…The interleukin-3 receptor α subunit, CD123, is expressed in many hematologic malignancies including acute myeloid leukemia (AML) and blastic plasmacytoid…”
Get full text

Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models by Beheshti, Afshin, Stevenson, Kristen, Vanderburg, Charles, Ravi, Dashnamoorthy, McDonald, J. Tyson, Christie, Amanda L., Shigemori, Kay, Jester, Hallie, Weinstock, David M., Evens, Andrew M.

“…There remains a need to identify new sensitive diagnostic and predictive blood-based platforms in lymphoma. We previously discovered a novel circulating…”
Get full text

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia by Wu, Shuo-Chieh, Li, Loretta S., Kopp, Nadja, Montero, Joan, Chapuy, Bjoern, Yoda, Akinori, Christie, Amanda L., Liu, Huiyun, Christodoulou, Alexandra, van Bodegom, Diederik, van der Zwet, Jordy, Layer, Jacob V., Tivey, Trevor, Lane, Andrew A., Ryan, Jeremy A., Ng, Samuel Y., DeAngelo, Daniel J., Stone, Richard M., Steensma, David, Wadleigh, Martha, Harris, Marian, Mandon, Emeline, Ebel, Nicolas, Andraos, Rita, Romanet, Vincent, Dölemeyer, Arno, Sterker, Dario, Zender, Michael, Rodig, Scott J., Murakami, Masato, Hofmann, Francesco, Kuo, Frank, Eck, Michael J., Silverman, Lewis B., Sallan, Stephen E., Letai, Anthony, Baffert, Fabienne, Vangrevelinghe, Eric, Radimerski, Thomas, Gaul, Christoph, Weinstock, David M.

“…A variety of cancers depend on JAK2 signaling, including the high-risk subset of B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements. Type…”
Get full text

KPT‐330 inhibitor of CRM1 (XPO1)‐mediated nuclear export has selective anti‐leukaemic activity in preclinical models of T‐cell acute lymphoblastic leukaemia and acute myeloid leukaemia by Etchin, Julia, Sanda, Takaomi, Mansour, Marc R., Kentsis, Alex, Montero, Joan, Le, Bonnie T., Christie, Amanda L., McCauley, Dilara, Rodig, Scott J., Kauffman, Michael, Shacham, Sharon, Stone, Richard, Letai, Anthony, Kung, Andrew L., Thomas Look, A.

“…Summary This study explored the anti‐leukaemic efficacy of novel irreversible inhibitors of the major nuclear export receptor, chromosome region maintenance 1…”
Get full text

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma by Battistello, Elena, Katanayeva, Natalya, Dheilly, Elie, Tavernari, Daniele, Donaldson, Maria C., Bonsignore, Luca, Thome, Margot, Christie, Amanda L., Murakami, Mark A., Michielin, Olivier, Ciriello, Giovanni, Zoete, Vincent, Oricchio, Elisa

“…In diffuse large B-cell lymphoma (DLBCL), activation of the B-cell receptor (BCR) promotes multiple oncogenic signals, which are essential for tumor…”
Get full text

Inhibition of USP10 induces degradation of oncogenic FLT3 by Weisberg, Ellen L, Schauer, Nathan J, Yang, Jing, Lamberto, Ilaria, Doherty, Laura, Bhatt, Shruti, Nonami, Atsushi, Meng, Chengcheng, Letai, Anthony, Wright, Renee, Tiv, Hong, Gokhale, Prafulla C, Ritorto, Maria Stella, De Cesare, Virginia, Trost, Matthias, Christodoulou, Alexandra, Christie, Amanda, Weinstock, David M, Adamia, Sophia, Stone, Richard, Chauhan, Dharminder, Anderson, Kenneth C, Seo, Hyuk-Soo, Dhe-Paganon, Sirano, Sattler, Martin, Gray, Nathanael S, Griffin, James D, Buhrlage, Sara J

“…An inhibitor of the deubiquitinase (DUB) USP10 regulates the degradation of oncogenic FLT3, thus defining USP10 as a DUB for FLT3 and providing a therapeutic…”
Get full text

Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas by Koch, Raphael, Christie, Amanda L., Crombie, Jennifer L., Palmer, Adam C., Plana, Deborah, Shigemori, Kay, Morrow, Sara N., Van Scoyk, Alexandria, Wu, Wenchao, Brem, Elizabeth A., Secrist, J. Paul, Drew, Lisa, Schuller, Alwin G., Cidado, Justin, Letai, Anthony, Weinstock, David M.

“…There is a pressing need for more effective therapies to treat patients with T-cell lymphomas (TCLs), including first-line approaches that increase the…”
Get full text

Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease by Chapuy, Bjoern, Cheng, Hongwei, Watahiki, Akira, Ducar, Matthew D., Tan, Yuxiang, Chen, Linfeng, Roemer, Margaretha G.M., Ouyang, Jing, Christie, Amanda L., Zhang, Liye, Gusenleitner, Daniel, Abo, Ryan P., Farinha, Pedro, von Bonin, Frederike, Thorner, Aaron R., Sun, Heather H., Gascoyne, Randy D., Pinkus, Geraldine S., van Hummelen, Paul, Wulf, Gerald G., Aster, Jon C., Weinstock, David M., Monti, Stefano, Rodig, Scott J., Wang, Yuzhuo, Shipp, Margaret A.

“…Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease defined by transcriptional classifications, specific signaling and survival pathways, and…”
Get full text

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition by Weigert, Oliver, Lane, Andrew A, Bird, Liat, Kopp, Nadja, Chapuy, Bjoern, van Bodegom, Diederik, Toms, Angela V, Marubayashi, Sachie, Christie, Amanda L, McKeown, Michael, Paranal, Ronald M, Bradner, James E, Yoda, Akinori, Gaul, Christoph, Vangrevelinghe, Eric, Romanet, Vincent, Murakami, Masato, Tiedt, Ralph, Ebel, Nicolas, Evrot, Emeline, De Pover, Alain, Régnier, Catherine H, Erdmann, Dirk, Hofmann, Francesco, Eck, Michael J, Sallan, Stephen E, Levine, Ross L, Kung, Andrew L, Baffert, Fabienne, Radimerski, Thomas, Weinstock, David M

“…Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic…”
Get full text

HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma by Jacobson, Caron, Kopp, Nadja, Layer, Jacob V., Redd, Robert A., Tschuri, Sebastian, Haebe, Sarah, van Bodegom, Diederik, Bird, Liat, Christie, Amanda L., Christodoulou, Alexandra, Saur, Amy, Tivey, Trevor, Zapf, Stefanie, Bararia, Deepak, Zimber-Strobl, Ursula, Rodig, Scott J., Weigert, Oliver, Weinstock, David M.

“…The Bruton tyrosine kinase (BTK) inhibitor ibrutinib induces responses in 70% of patients with relapsed and refractory mantle cell lymphoma (MCL). Intrinsic…”
Get full text

A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas by Ryan, Russell J.H., Petrovic, Jelena, Rausch, Dylan M., Zhou, Yeqiao, Lareau, Caleb A., Kluk, Michael J., Christie, Amanda L., Lee, Winston Y., Tarjan, Daniel R., Guo, Bingqian, Donohue, Laura K.H., Gillespie, Shawn M., Nardi, Valentina, Hochberg, Ephraim P., Blacklow, Stephen C., Weinstock, David M., Faryabi, Robert B., Bernstein, Bradley E., Aster, Jon C., Pear, Warren S.

“…Gain-of-function Notch mutations are recurrent in mature small B cell lymphomas such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), but…”
Get full text

Mutations in G protein β subunits promote transformation and kinase inhibitor resistance by Yoda, Akinori, Adelmant, Guillaume, Tamburini, Jerome, Chapuy, Bjoern, Shindoh, Nobuaki, Yoda, Yuka, Weigert, Oliver, Kopp, Nadja, Wu, Shuo-Chieh, Kim, Sunhee S, Liu, Huiyun, Tivey, Trevor, Christie, Amanda L, Elpek, Kutlu G, Card, Joseph, Gritsman, Kira, Gotlib, Jason, Deininger, Michael W, Makishima, Hideki, Turley, Shannon J, Javidi-Sharifi, Nathalie, Maciejewski, Jaroslaw P, Jaiswal, Siddhartha, Ebert, Benjamin L, Rodig, Scott J, Tyner, Jeffrey W, Marto, Jarrod A, Weinstock, David M, Lane, Andrew A

“…The authors identify mutations in β subunits of G proteins that promote transformation and therapy resistance. Activating mutations in genes encoding G protein…”
Get full text

Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents by Lossos, Chen, Liu, Yunpeng, Kolb, Kellie E, Christie, Amanda L, Van Scoyk, Alexandria, Prakadan, Sanjay M, Shigemori, Kay, Stevenson, Kristen E, Morrow, Sara, Plana, Olivia D, Fraser, Cameron, Jones, Kristen L, Liu, Huiyun, Pallasch, Christian P, Modiste, Rebecca, Nguyen, Quang-De, Craig, Jeffrey W, Morgan, Elizabeth A, Vega, Francisco, Aster, Jon C, Sarosiek, Kristopher A, Shalek, Alex K, Hemann, Michael T, Weinstock, David M

“…The extraordinary activity of high-dose cyclophosphamide against some high-grade lymphomas was described nearly 60 years ago. Here we address mechanisms that…”
Get more information